1. Home
  2. Stocks
  3. Mankind Share Price

Mankind Pharma Share Price

Pharmaceuticals Large Cap

₹2,714.25 -16.95 (-0.62%)

05 Nov, 2024 19:05

SIP TrendupStart SIP in MANKIND

Start SIP
Performance Financial Technical Events FnO Shareholding Pattern More FAQ’s

Performance

  • Low
  • ₹2,652
  • High
  • ₹2,730
  • 52 Week Low
  • ₹1,733
  • 52 Week High
  • ₹2,835
  • Open Price₹2,730
  • Previous Close₹2,731
  • Volume179,946

Investment Returns

  • Over 1 Month + 3.93%
  • Over 3 Month + 35.71%
  • Over 6 Month + 17.25%
  • Over 1 Year + 52.91%
SIP Lightning

Smart Investing Starts Here Start SIP with Mankind Pharma for Steady Growth!

Mankind Pharma Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 55.4
  • PEG Ratio
  • 1.7
  • Market Cap Cr
  • 108,745
  • P/B Ratio
  • 11.4
  • Average True Range
  • 95.83
  • EPS
  • 42.8
  • Dividend Yield
  • 0
  • MACD Signal
  • 19.68
  • RSI
  • 59.42
  • MFI
  • 55.86

Mankind Pharma Financial

IndicatorJun 24Mar 24Dec 23Sep 23Jun 23
Net Sales/Income from operations2,403.262,152.692,358.572,453.352,300.21
Total Income From Operations2,403.262,152.692,358.572,453.352,300.21
P/L Before Interest, Excpt. Items & Tax583.63548.89580.61616.27528.36
P/L Before Exceptional Items & Tax577.37544.86576.35611.96526.39
P/L After Tax from Ordinary Activities484.25454.17487.07472.88409.28
Net Profit/Loss For the Period513.49454.17487.07472.88409.28
IndicatorMar 24Mar 23
Revenue From Operations [Gross]9,263.668,120.57
Revenue From Operations [Net]9,263.668,120.57
Total Operating Revenues9,264.818,127.15
Total Revenue9,531.458,289.94
Total Expenses7,271.886,727.10
Profit/Loss Before Tax2,259.571,562.84
Profit/Loss For The Period1,823.411,248.26
IndicatorMar 24Mar 23
Net CashFlow - Operating Activity1,982.971,798.99
Net Cash Used In Investing Activity-1,919.12-1,040.61
Net Cash Used in Finance Activity-8.68-710.41
Net Inc/Dec In Cash And Equivalent55.0747.96
Cash And Equivalent End Of Year189.20134.13
IndicatorMar 24Mar 23
Total Share Capital40.0640.06
Total Non-Current Liabilities200.54168.12
Total Current Liabilities1,593.361,419.09
Total Capital And Liabilities11,417.719,371.12
Total Non-Current Assets5,927.305,854.21
Total Current Assets5,490.413,516.91
Total Assets11,417.719,371.12
Indicator20242023
EBIT Margin (%)24.5419.57
Return On Capital Employed (%)23.1420.00
Return On Equity (%)18.9416.03
Long Term Debt To Equity (%)0.000.00
Book Value/Share (INR)240.24194.31
IndicatorJun 24Mar 24Dec 23Sep 23Jun 23
Net Sales/Income from operations2,893.422,441.102,606.962,708.102,578.62
Total Income From Operations2,893.422,441.102,606.962,708.102,578.62
P/L Before Interest, Excpt. Items & Tax674.62578.54566.91646.14626.08
P/L Before Exceptional Items & Tax663.71569.16557.73637.52619.74
P/L After Tax from Ordinary Activities539.16474.18455.21507.71489.46
Net Profit/Loss For the Period539.16474.18455.21507.71489.46
IndicatorMar 24Mar 23
Revenue From Operations [Gross]10,333.638,742.85
Revenue From Operations [Net]10,333.638,742.85
Total Operating Revenues10,334.778,749.43
Total Revenue10,615.638,878.00
Total Expenses8,231.497,219.18
Profit/Loss Before Tax2,384.141,658.81
Profit/Loss For The Period1,926.561,297.25
IndicatorMar 24Mar 23
Net CashFlow - Operating Activity2,152.451,813.30
Net Cash Used In Investing Activity-2,081.69-1,054.13
Net Cash Used in Finance Activity5.27-739.73
Net Inc/Dec In Cash And Equivalent77.1921.76
Cash And Equivalent End Of Year382.01304.82
IndicatorMar 24Mar 23
Total Share Capital40.0640.06
Total Non-Current Liabilities267.74229.02
Total Current Liabilities2,119.731,863.14
Total Capital And Liabilities11,963.259,715.45
Total Non-Current Assets5,395.035,387.58
Total Current Assets6,568.234,327.87
Total Assets11,963.259,715.45
Indicator20242023
EBIT Margin (%)23.3919.46
Return On Capital Employed (%)24.5621.69
Return On Equity (%)20.4317.24
Long Term Debt To Equity (%)0.260.31
Book Value/Share (INR)239.04190.30

Mankind Pharma Technicals

EMA & SMA

Current Price
₹2,714.25
-16.95 (-0.62%)
pointer
  • stock-down_img
  • Bullish Moving Average 16
  • stock-up_img
  • Bearish Moving Average 0
  • 20 Day
  • ₹2,618.68
  • 50 Day
  • ₹2,538.15
  • 100 Day
  • ₹2,424.00
  • 200 Day
  • ₹2,269.38

Resistance and Support

2698.82 Pivot Speed
  • R3 2,823.23
  • R2 2,776.62
  • R1 2,745.43
  • S1 2,667.63
  • S2 2,621.02
  • S3 2,589.83

Is Mankind Pharma Worth Buying?

BUY SELL HOLD

You can only vote for once

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Mankind Pharma Ltd. is one of India’s largest pharmaceutical companies, providing a wide range of affordable medicines in areas like antibiotics, cardiovascular, gastrointestinal, and dermatology. It also manufactures over-the-counter (OTC) products, catering to domestic and global markets. Mankind Pharma Ltd has an operating revenue of Rs. 10,649.58 Cr. on a trailing 12-month basis. An annual revenue growth of 20% is outstanding, Pre-tax margin of 23% is great, ROE of 20% is exceptional. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is comfortably placed above its key moving averages, around 5% and 17% from 50DMA and 200DMA. From an O'Neil Methodology perspective, the stock has an EPS Rank of 79 which is a FAIR score but needs to improve its earnings, a RS Rating of 74 which is FAIR indicating the recent price performance, Buyer Demand at A which is evident from recent demand for the stock, Group Rank of 41 indicates it belongs to a fair industry group of Medical-Products and a Master Score of B is close to being the best. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock definitely has some strength, you may want to examine it in more detail. Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation. (+)

Mankind Pharma Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2024-11-05 Quarterly Results
2024-07-31 Quarterly Results
2024-05-15 Audited Results & Others To evaluate various options or proposals for raising funds through any of the permissible modes, subject to the receipt of necessary approvals.
2024-01-31 Quarterly Results
2023-10-31 Quarterly Results

Mankind Pharma F&O

Mankind Pharma Shareholding Pattern

74.87%
6.99%
2.34%
12.37%
0%
1.55%
1.88%
  • NSE Symbol
  • MANKIND
  • BSE Symbol
  • 543904
  • ISIN
  • INE634S01028

Mankind Pharma FAQs

Mankind Pharma share price is ₹2,714 As on 05 November, 2024 | 18:51

The Market Cap of Mankind Pharma is ₹108744.8 Cr As on 05 November, 2024 | 18:51

The P/E ratio of Mankind Pharma is 55.4 As on 05 November, 2024 | 18:51

The PB ratio of Mankind Pharma is 11.4 As on 05 November, 2024 | 18:51

Q2FY23
Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91
 
footer_form

The Vigilance Awareness Week for the year 2024 (VAW 2024) would be observed from October 28, 2024 to November 03, 2024
“सत्यनिष्ठा की संस्कृनि सेराष्र की समद्ृधि” “Culture of Integrity for Nation's Prosperity”
e-pledge link (https://pledge.cvc.nic.in/)

5paisa Capital Ltd. CIN: L67190MH2007PLC289249 | Stock Broker SEBI Regn.: INZ000010231 | SEBI RA Regn.: INH000004680 | SEBI Depository Regn.: IN DP CDSL: IN-DP-192-2016 | AMFI-registered Mutual Fund Distributor | AMFI REGN No.: ARN-104096 | Date of initial Registration: 30/07/2015 | Current validity of ARN : 30/07/2027 | NSE Member id: 14300 | BSE Member id: 6363 | MCX Member ID: 55945 | Investment Adviser Regn No: INA000014252 | Registered Address - IIFL House, Sun Infotech Park, Road no. 16V, Plot no. B-23, MIDC, Thane Industrial Area, Waghle Estate, Thane, Maharashtra - 400604

*Brokerage will be levied flat fee/executed order basis and not on a percentage basis. Investment in securities market are subject to market risk, read all related documents carefully before investing. Digital account would be opened after all procedure relating to IPV and client due diligence is completed. If sale/ purchase value of share of ₹10/- or less, a maximum brokerage of 25 paisa per share may be collected. Brokerage will not exceed the SEBI prescribed limit.

Compliance Officer: Ms. Namita Godbole, Email: support@5paisa.com, Support Desk Helpline: 8976689766

Contact Us

Attention Investors

  • 1. No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account.
  • 2. Message from Exchange(s): Prevent Unauthorised transactions in your account --> Update your mobile numbers/email IDs with your stock brokers. Receive information of your transactions directly from Exchange on your mobile/email at the end of the day. Issued in the interest of investors.
  • 3. Message from Depositories: a) Prevent Unauthorized Transactions in your demat account --> Update your mobile number with your Depository Participant. Receive alerts on your registered mobile for all debit and other important transactions in your demat account directly from CDSL on the same day issued in the interest of investors. b) KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.

Email: support@5paisa.com

Support Desk Helpline: 8976689766

©2024, 5paisa Capital Ltd. All Rights Reserved. We are ISO 27001:2013 Certified.